| Drug Name |
Tapentadol hydrochloride |
| Drug ID |
BADD_D02116 |
| Description |
Opioid analgesic for treatment of moderate to severe pain. FDA approved on Nov 20, 2008. |
| Indications and Usage |
The immediate-release formulation of tapentadol is indicated for the relief of moderate to severe acute pain. The long-acting formulation serves as a continuous, around-the-clock analgesic that is indicated for the relief of moderate to severe chronic pain or neuropathic pain associated with diabetic peripheral neuropathy. |
| Marketing Status |
approved |
| ATC Code |
N02AX06 |
| DrugBank ID |
DB06204
|
| KEGG ID |
D10199
|
| MeSH ID |
D000077432
|
| PubChem ID |
9838021
|
| TTD Drug ID |
D0K4MH
|
| NDC Product Code |
65267-101; 24510-100; 24510-116; 24510-075; 24510-174; 24510-291; 24510-050; 24510-232; 17180-9780; 24510-058; 0792-5671 |
| UNII |
71204KII53
|
| Synonyms |
Tapentadol | 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)phenol | Nucynta | Tapentadol Hydrochloride |
